When a child is diagnosed with type 1 diabetes, both the child and family members will need to learn how to manage their ...

Take the type 1 diabetes (T1D) space, as one example. Today, new and exciting advancements are working to reduce barriers, ...

Tourmaline Bio's Pacibekitug shows promise in IL-6 targeting for autoimmune diseases. Learn about its potential and ongoing trials. Read why TRML is a hold.

Delaware courts issued multiple instructive decisions on earnout provisions in life sciences M&A transactions.

City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the United States and a ...

A new study published in the journal of BMC Nephrology showed that in individuals with primary membranous nephropathy (PMN), ...

Checkpoint Therapeutics, Inc. ("Checkpoint”) (Nasdaq: CKPT), a commercial-stage immunotherapy and targeted oncology company, ...

Adopting early testing best practices with widescale T1D screening programs across Europe could mitigate the ‘invisible burden’ of diabetes.

According to Dealroom, in Q1 2025, European startups have secured $15.8B through nearly 1,600 funding rounds. From AI and fintech to clean energy and biotech, startups have attracted large amounts of ...

AstraZeneca's IMFINZI® (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by IMFINZI as adjuvant monotherapy after radical cystectomy (surgery to remove the ...

AstraZeneca’s IMFINZI® (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by IMFINZI as adjuvant monotherapy after radical cystectomy (surgery to remove the ...

Checkpoint Therapeutics, Inc. ("Checkpoint") (Nasdaq: CKPT), a commercial-stage immunotherapy and targeted oncology company, today announced financial ...